
|Slideshows|May 18, 2018
EMPA-REG OUTCOME: Analysis in Women with T2DM and CVD
Author(s)Veronica Hackenthal, MD
A recent trial found that empagliflozin can reduce the risk of cardiovascular deaths in type 2 diabetes patients; are results similar in men and women?
Advertisement
  Â
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Sanofi Announces Discontinuation of Amlitelimab for Atopic Dermatitis
2
FDA Approves Furosemide Injection (Furoscix ReadyFlow) for Edema in HF, CKD
3
Dupilumab, Depemokimab, and COPD: What APPs See in Practice
4
Why Does IgA Nephropathy Affect More Men? With Ramy Hanna, MD
5











































































